Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.52
$0.52
$0.52
▼
$29.97
$1.42MN/A5.06 million shsN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
$0.42
-13.4%		$0.93
$0.34
▼
$44.70
$433K1.281.87 million shs1.48 million shs
Atrinsic Inc. stock logo
PTIX
Atrinsic
$0.75
-6.3%		$0.77
$0.13
▼
$3.32
$1.36M1.8427,332 shs161 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$1.26
-13.1%		$3.23
$1.11
▼
$75.50
$1.12M1.8549,391 shs13.19 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
0.00%0.00%0.00%0.00%-90.84%
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
+37.06%-14.86%-57.14%-77.46%-98.86%
Atrinsic Inc. stock logo
PTIX
Atrinsic
-0.74%+3.90%-3.61%+207.34%-73.60%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
-6.45%-33.79%-30.95%-88.12%-98.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.52
$0.52
$0.52
▼
$29.97
$1.42MN/A5.06 million shsN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
$0.42
-13.4%		$0.93
$0.34
▼
$44.70
$433K1.281.87 million shs1.48 million shs
Atrinsic Inc. stock logo
PTIX
Atrinsic
$0.75
-6.3%		$0.77
$0.13
▼
$3.32
$1.36M1.8427,332 shs161 shs
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$1.26
-13.1%		$3.23
$1.11
▼
$75.50
$1.12M1.8549,391 shs13.19 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
0.00%0.00%0.00%0.00%-90.84%
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
+37.06%-14.86%-57.14%-77.46%-98.86%
Atrinsic Inc. stock logo
PTIX
Atrinsic
-0.74%+3.90%-3.61%+207.34%-73.60%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
-6.45%-33.79%-30.95%-88.12%-98.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abpro Holdings Inc. stock logo
ABP
Abpro
1.50
ReduceN/AN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
1.00
SellN/AN/A
Atrinsic Inc. stock logo
PTIX
Atrinsic
1.00
SellN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BDRX, VBIO, PTIX, and ABP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2026
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E) ➝ Sell (E+)
9/28/2026
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (E+) ➝ Sell (E)
9/14/2026
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
7/17/2026
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/A($8.83) per shareN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
N/AN/AN/AN/A$110.30 per shareN/A
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/AN/AN/AN/A$1.96 per shareN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
$780K1.44N/AN/A$166.26 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abpro Holdings Inc. stock logo
ABP
Abpro
-$7.23M-$4.23N/AN/AN/AN/AN/A-344.76%N/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
-$8.42MN/AN/AN/AN/AN/AN/AN/AN/A
Atrinsic Inc. stock logo
PTIX
Atrinsic
-$5.53M$2.23N/AN/AN/AN/AN/A-379.72%11/17/2026 (Estimated)
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
-$8.88M-$159.25N/AN/AN/AN/A-193.17%-67.10%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
N/AN/AN/AN/AN/A
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/AN/AN/AN/AN/A
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A
0.07
0.07
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
N/A
2.41
N/A
Atrinsic Inc. stock logo
PTIX
Atrinsic
N/A
0.29
0.29
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
1.74
1.11
0.86

Institutional Ownership

CompanyInstitutional Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
23.30%
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
17.51%
Atrinsic Inc. stock logo
PTIX
Atrinsic
7.97%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
4.25%

Insider Ownership

CompanyInsider Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
13.70%
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
0.34%
Atrinsic Inc. stock logo
PTIX
Atrinsic
8.00%
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abpro Holdings Inc. stock logo
ABP
Abpro
152.72 million2.34 millionN/A
Biodexa Pharmaceuticals PLC Unsponsored ADR stock logo
BDRX
Biodexa Pharmaceuticals
111.03 million1.03 millionNot Optionable
Atrinsic Inc. stock logo
PTIX
Atrinsic
21.81 million1.78 millionNot Optionable
Valion Bio, Inc. Common Stock stock logo
VBIO
Valion Bio, Inc. Common Stock
10890,000866,000Not Optionable

Recent News About These Companies

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
October 15 at 8:00 AM  |  accessnewswire.comA
With Section 232 Tariffs Reshaping Biotech, Valion Bio’s Velocity Bioworks Capitalizes on Domestic CDMO Surge
October 14 at 1:27 PM  |  biospace.comB
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
October 14 at 8:15 AM  |  accessnewswire.comA
Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Shares Shorted: Short Interest Up 128.9% in September
October 13 at 7:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114621
Valion Bio (NASDAQ: VBIO) lines up $50,000 Series B financing step
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107389
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should ...
October 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/ACCESS/5323814/valion-bio-nasdaqvbio-oral-mucosal-entolimod-could-offer-a-new-needle-free-deployment-path-to-support-growing-need-for-scalable-civilian-radiation-preparedness-should-nuclear-infrastructure-expand-to-support-data-centers/
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
October 9, 2026  |  accessnewswire.comA
Valion Bio (NASDAQ: VBIO) taps Jensen to steer Entolimod with $35.6 million
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097816
Valion Chair Jensen Outlines Focus On Entolimod Development; Stock Down
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696546/valion-chair-jensen-outlines-focus-on-entolimod-development-stock-down.aspx
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
October 5, 2026  |  accessnewswire.comA
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
September 30, 2026  |  accessnewswire.comA
Valion Bio, Inc. Announces Appointment of Dean Zikria as Interim Chief Executive Officer
September 25, 2026  |  marketscreener.comM
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23, 2026  |  accessnewswire.comA
Valion Bio, Inc.: Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69644124-valion-bio-inc-valion-bio-regains-compliance-with-nasdaq-minimum-bid-price-listing-rule-200.htm
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22, 2026  |  accessnewswire.comA
VBIO - Valion Bio, Inc.
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/VBIO/historical-price-quotes
Valion Bio Announces Changes to Management and Board of Directors
September 1, 2026  |  accessnewswire.comA
Valion Bio's Reverse Stock Split Takes Effect Today, August 31, 2026; Stock Up
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687070/valion-bio-s-reverse-stock-split-takes-effect-today-august-31-2026-stock-up.aspx
Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split
August 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69425881-valion-bio-inc-valion-bio-announces-reverse-stock-split-200.htm
Valion Bio Inc VBIO
August 25, 2026  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abpro stock logo

Abpro NASDAQ:ABP

$0.52 0.00 (0.00%)
As of 10/14/2026

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Biodexa Pharmaceuticals stock logo

Biodexa Pharmaceuticals NASDAQ:BDRX

$0.42 -0.06 (-13.38%)
As of 02:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Atrinsic stock logo

Atrinsic NASDAQ:PTIX

$0.75 -0.05 (-6.25%)
As of 09:30 AM Eastern

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Valion Bio, Inc. Common Stock stock logo

Valion Bio, Inc. Common Stock NASDAQ:VBIO

$1.26 -0.19 (-13.10%)
As of 02:13 PM Eastern

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas